Correlations Between Serum IL33 and Tumor Development: a Meta-analysis |
Chen, Xiang-Jun
(Department of Medical Quality Control, West China Hospital, Sichuan University)
Huang, Ying-De (Department of Medical Quality Control, West China Hospital, Sichuan University) Li, Nian (Department of Medical Quality Control, West China Hospital, Sichuan University) Chen, Min (Department of Medical Quality Control, West China Hospital, Sichuan University) Liu, Fang (Department of Medical Quality Control, West China Hospital, Sichuan University) Pu, Dan (Clinical Skill Experiment Teaching Center, West China Hospital, Sichuan University) Zhou, Tao-You (Department of Infectious Disease, West China Hospital, Sichuan University) |
1 | Williams MA, Bevan MJ (2007). Effector and memory CTL differentiation, Annu Rev Immunol, 25, 171-92. DOI ScienceOn |
2 | Schmitz J, Owyang A, Oldham E, et al (2005). IL-33, an interleukin-1-likecytokine that signals via the IL-1 receptorrelated protein ST2 and induces Thelper type 2-associated cytokines. Immunity, 23, 479–90. DOI ScienceOn |
3 | Sun P, Ben Q, Tu S, et al (2011). Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci, 56, 3596-601. DOI ScienceOn |
4 | Walzl G, Matthews S, Kendall S, et al (2001). Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)-but not Th1-driven immunopathology. J Exp Med, 193, 785-92. DOI |
5 | Zhang P, Liu XK, Chu Z, et al (2012). Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications. J Int Med Res, 40, 1654-61. DOI |
6 | Kakkar R and Lee RT (2008). The IL-33/ST2 pathway:therapeutic target and novel biomarker. Nat Rev Drug Discov, 7, 827–40. DOI ScienceOn |
7 | Humphreys NE, Xu D, Hepworth MR, et al (2008). IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J Immunol, 180, 2443-9. DOI |
8 | Jovanovic IP, Pejnovic NN, Radosavljevic GD, et al (2014). Interleukin-33/ST2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer, 134, 1669-82. DOI ScienceOn |
9 | Jovanovic I, Radosavljevic G, Mitrovic M, et al (2011). ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immuno, l41, 1902-12. DOI ScienceOn |
10 | Liew FY, Pitman N, McInnes IB (2010). Disease-associated functions of IL-33: the new kid in the IL-1 family, Nat Rev Immunol, 10, 103-10. DOI ScienceOn |
11 | Lopetuso LR, Scaldaferri F, Pizarro TT (2012). Emerging role of the interleukin (IL)-33/ST2 axis in gut mucosal wound healing and fibrosis. Fibrogenesis Tissue Repair, 5, 18. DOI ScienceOn |
12 | Naumnik W, Naumnik B, Niewiarowska K, et al (2012). Novel cytokines: IL-27, IL-29, IL-31 and IL-33. Can they be useful in clinical practice at the time diagnosis of lung cancer?Exp Oncol, 34, 348-53. |
13 | Oshikawa K, Yanagisawa K, Ohno S, et al (2002). Expression of ST2 in helper T lymphocytes of malignant pleural effusions. Am J Respir Crit Care Med, 165, 1005-9. DOI ScienceOn |
14 | Roy A, Ganesh G, Sippola H, et al (2014). Mast Cell Chymase Degrades the Alarmins Heat Shock Protein 70, Biglycan, HMGB1, and Interleukin-33 (IL-33). and Limits Dangerinduced Inflammation. J Biol Chem, 289, 237-50. DOI ScienceOn |
15 | Santulli P, Even M, Chouzenoux S, et al (2013). Profibrotic interleukin-33 is correlated with uterine leiomyoma tumour burden. Hum Reprod, 28, 2126-33. DOI ScienceOn |
16 | Bourgeois E, Van LP, Samson M, et al (2009). The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol, 39, 1046–55. DOI ScienceOn |
17 | Arshad MI, Piquet-Pellorce C, Samson M (2012). IL-33 and HMGB1 alarmins: sensors of cellular death and their involvement in liver pathology. Liver Int, 32, 1200-10. DOI ScienceOn |
18 | Bergis D, Kassis V, Ranglack A, et al (2013). High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma. Transl Oncol, 6, 311-8. DOI |
19 | Bonilla WV, Frohlich A, Senn K, et al (2012). The alarmin interleukin-33 drives protective antiviral CD8 (+). T cell responses. Science, 335, 984-9. DOI ScienceOn |
20 | Chackerian AA, Oldham ER, Murphy EE, et al (2007). IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol, 179, 2551–5. DOI |
21 | Dobrzanski MJ, Reome JB, Hylind JC, et al (2006). CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol, 177, 8191-201. DOI |
22 | Gangemi S, Allegra A, Profita M, et al (2013). Decreased plasma levels of IL-33 could contribute to the altered function of Th2 lymphocytes in patients with polycythemia vera and essential thrombocythemia. Cancer Invest, 31, 212-3. DOI ScienceOn |
23 | Hu LA, Fu Y, Zhang DN, et al (2013). Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2563-6. 과학기술학회마을 DOI ScienceOn |
24 | Chen SF, Nieh S, Jao SW, et al (2013). The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol, 231, 180-9. DOI ScienceOn |